公开(公告)号：US20140341922A1

公开(公告)日：2014-11-20

申请号：US14360117

申请日：2012-11-23

Applicant: SUN R&DB Foundation

Inventor： Ho Young Lee

IPC: C07K16/28 ,  A61K31/519 ,  G01N33/574 ,  A61K39/395

CPC classification number: C07K16/2848 ,  A61K31/519 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/73 ,  G01N33/5011 ,  G01N33/57407 ,  G01N33/57492 ,  G01N2800/52 ,  A61K2300/00

Abstract: Provided are a pharmaceutical composition for suppressing a resistance to a targeted anticancer drug, which at least one selected from the group consisting of an integrin β3 neutralizing antibody, integrin β3 siRNA, Src inhibitor, and Src siRNA as an active ingredient, and an anticancer supplement. The pharmaceutical composition may increase an anticancer therapeutic effect when administered in combination with a conventional targeted anticancer drug. In addition, the pharmaceutical composition is expected to be used in development of an integrin β3-targeted targeted anticancer drug.

Abstract translation: 本发明提供了抑制靶向抗癌药物的抗性的药物组合物，其中选自由整联蛋白3中和抗体，整联蛋白3，siRNA，Src抑制剂和Src siRNA作为有效成分组成的组中的至少1种， 和抗癌补品。 当与常规靶向抗癌药物组合施用时，药物组合物可以增加抗癌治疗效果。 此外，药物组合物预期用于开发整合素和靶向靶向抗癌药物。